INCB123667

INCB123667 is Incyte's selective CDK2 inhibitor targeting platinum-resistant ovarian cancer (PROC) in patients whose tumors overexpress cyclin E1 - a population with dismal outcomes on standard chemotherapy and no targeted therapy options. Phase 1 data showed a 33% response rate at the recommended dose, and Incyte has moved fast into a Phase 3 trial (MAESTRA-2) against investigator's choice chemo. If it works, this would be the first approved therapy to directly exploit the cyclin E1 vulnerability in ovarian cancer - a gap the field has been circling for years.

INCB123667 is a novel, never-approved compound. Incyte initiated two registrational-track studies in Q4 2025: MAESTRA-1 (Phase 2 single-arm, NCT07023627, n=160) and MAESTRA-2 (Phase 3 randomized, NCT07214779, n=466) [1][2]. Both NCT identifiers have been verified against ClinicalTrials.gov. Both trials target PROC patients with cyclin E1 overexpression. A Phase 1 dose-finding study (NCT05238922) remains active and is also evaluating the drug in breast and endometrial cancers with CCNE1 aberrations [3]. Incyte has disclosed plans to initiate a Phase 3 in first-line maintenance ovarian cancer in 2026 [4]. The company has not announced any FDA designations (breakthrough, fast track, or orphan) for INCB123667 to date. Given the MAESTRA-2 trial started recruiting in late 2025 with a target of 466 patients, a primary PFS readout is likely in 2028, though Incyte has hinted at discussions with the FDA about accelerated approval based on the single-arm MAESTRA-1 data, which could come sooner [4]. The drug is also being studied in a Phase 1 food-effect and drug-drug interaction trial (NCT06909162), indicating active pharmaceutical development work on the commercial formulation [5]. Notably, no FDA-cleared companion diagnostic exists for cyclin E1 IHC. Both MAESTRA trials use a sponsor-developed IHC assay to define cyclin E1 overexpression, but this has not been submitted for regulatory clearance. A systematic review of CCNE1 IHC found that sensitivity and specificity for detecting CCNE1 amplification vary widely (54-100% and 57-90% across studies), and optimal cutoff thresholds remain debated [11]. Whether Incyte is co-developing a CDx with a diagnostics partner has not been publicly disclosed - this is a regulatory gap that will need to be closed before approval.

Here's the biology. Cells divide by progressing through a cycle with built-in checkpoints. One of the key gatekeepers of that cycle is CDK2, a protein that acts like a green light for cells to copy their DNA and start dividing. CDK2 needs a partner to work - cyclin E1 - and when cyclin E1 is overproduced (which happens when the CCNE1 gene is amplified or dysregulated), the CDK2-cyclin E1 pair fires too aggressively, pushing cells into DNA replication before they're ready. This creates replication stress - think of it as a factory running so fast that quality control breaks down, generating defective products (damaged DNA) [6]. The cell becomes addicted to this broken machinery. INCB123667 blocks CDK2 with roughly 50-fold selectivity over other related kinases (CDK1, CDK4, CDK6), shutting down the overactive cell cycle engine specifically in tumors that depend on it [7]. What makes this mechanism especially relevant for ovarian cancer: cyclin E1 overexpression is essentially mutually exclusive with homologous recombination deficiency (HRD). HRD is a DNA repair defect that leaves tumors unable to fix double-strand breaks through the normal high-fidelity pathway, making them dependent on a backup repair mechanism - and PARP inhibitors like olaparib exploit exactly this vulnerability by blocking that backup, causing tumor cells to accumulate lethal DNA damage. Cyclin E1-high tumors typically have intact homologous recombination, which is why PARP inhibitors don't work in them [6]. This creates a biomarker-defined treatment gap: cyclin E1-high patients have poor prognosis, poor response to platinum, and no targeted options. CDK2 inhibition is the first mechanism that directly attacks the molecular driver in these tumors rather than working around it.

MAESTRA-2 (NCT07214779) is a Phase 3, randomized, open-label study enrolling 466 patients with platinum-resistant ovarian cancer whose tumors show cyclin E1 overexpression by immunohistochemistry [1]. Patients are randomized to INCB123667 100 mg once daily versus investigator's choice of single-agent chemotherapy (likely paclitaxel, pegylated liposomal doxorubicin, topotecan, or gemcitabine - the standard options in this setting). The primary endpoint is progression-free survival assessed by blinded independent central review (BICR). The choice of PFS over overall survival as the primary endpoint is pragmatic - OS in platinum-resistant ovarian cancer is confounded by extensive post-progression therapy, and PFS is an accepted regulatory endpoint in this setting. The open-label design is standard for chemotherapy comparators. Running parallel is MAESTRA-1 (NCT07023627), a single-arm Phase 2 in 160 CCNE1-overexpressing PROC patients with objective response rate by independent review as the primary endpoint [2]. This dual-track strategy is shrewd: MAESTRA-1 could support accelerated approval on response rate while MAESTRA-2 provides the confirmatory randomized data. Enrollment requires prospective CCNE1 testing via IHC, which will slow recruitment somewhat but enriches for the population most likely to respond - the Phase 1 showed that nearly all responders had cyclin E1 overexpression [7]. A key open question is the IHC cutoff threshold: published literature shows that the sensitivity and specificity of cyclin E1 IHC for detecting underlying CCNE1 gene amplification vary substantially depending on the scoring method used, with one validated approach requiring >60% tumor cell positivity with >5% strong staining [11]. Whether the MAESTRA trials use the same threshold as the Phase 1 has not been disclosed; if the cutoff differs, the enrichment quality and therefore the expected response rate could shift.

Our model puts the probability of this drug eventually being approved at 57%. That starting point comes from looking at how often drugs at this stage in this area have historically made it through - roughly 48% of the time. From there, the model adjusts based on ten pieces of information about the trial and the sponsor; in this case, strong results from earlier testing, the trial's design, more endpoints than usual, and the sponsor's track record of approvals all push the number upward. The remaining factors fall close to average for this stage, so they don't shift the estimate much in either direction.

The primary efficacy risk is that CDK2 inhibition alone may not be enough. Cyclin E1 can drive proliferation through CDK2-independent mechanisms, and CDK1 can compensate for CDK2 loss in some tumor contexts [6]. If a meaningful fraction of CCNE1-high tumors use these escape routes, the Phase 3 response rate could dilute below what was seen in the selected Phase 1 cohort. The immunohistochemistry-based biomarker selection introduces additional uncertainty: no FDA-cleared companion diagnostic exists for cyclin E1 IHC, sensitivity and specificity for detecting CCNE1 amplification vary widely across published studies (54-100% and 57-90% respectively), and the threshold for "overexpression" matters enormously for enrichment quality [11]. If the IHC assay captures a broader population than the underlying biology supports, the treatment effect will be diluted. On safety, the Phase 1 showed manageable but real hematologic toxicity: thrombocytopenia (35% any grade, 13% Grade 3), anemia (30%, 7% Grade 3), and neutropenia (26%, 8% Grade 3) [7][9]. In a population already battered by prior chemotherapy lines, these rates could worsen and lead to dose reductions that erode efficacy. Execution risk centers on the biomarker screening requirement - not all PROC patients will have tissue available for CCNE1 testing, and the screening failure rate could slow enrollment. Commercially, even if approved, the addressable population is relatively narrow: roughly 20-30% of PROC patients will be CCNE1-high, which translates to approximately 3,000-5,000 eligible patients per year in the US. At $15,000-20,000/month and a median treatment duration of ~5 months, this implies a US peak revenue potential of roughly $250-500M annually, with meaningful ex-US upside. Pricing would need to be aggressive to make this commercially transformative for Incyte. The competitive landscape is active. In the same CDK2 mechanism class, Pfizer's tegtociclib (PF-07104091) is in Phase 1/2 dose expansion in ovarian cancer (NCT04553133) [13], and Blueprint Medicines' BLU-222 is in Phase 1/2 (VELA trial, NCT05252416) with a CCNE1-amplified PROC cohort in dose expansion [14]. Neither is yet in registrational trials, putting INCB123667 ahead on the CDK2 timeline. However, the most immediate competitive threat comes from a different mechanism class: Zentalis Pharmaceuticals' azenosertib, a WEE1 inhibitor targeting the same CCNE1-selected PROC population, already has FDA fast track designation (granted January 2025) and expects topline data from the DENALI Part 2 trial by end of 2026 [10]. Azenosertib's ORR in cyclin E1-positive patients (35% in the Phase 1b) is comparable to INCB123667's, and the FDA fast track designation gives Zentalis a regulatory head start that Incyte currently lacks.

Worth watching closely. INCB123667 represents a genuine attempt to drug a well-defined molecular vulnerability in ovarian cancer, not a me-too entry in a crowded checkpoint inhibitor market. The Phase 1 data is legitimately encouraging - 33% ORR in platinum-resistant disease is a real signal, and the biomarker enrichment strategy is scientifically sound. Incyte's decision to run parallel Phase 2 and Phase 3 tracks suggests they're confident enough to pursue accelerated approval while building the confirmatory dataset. The key data point to watch: MAESTRA-1 response rate data, which could read out in 2027 and potentially support an accelerated filing. If ORR holds above 25% with durable responses in the Phase 2, the accelerated approval pathway becomes viable. The competitive race against azenosertib (WEE1 inhibitor from Zentalis Pharmaceuticals, different mechanism, same patient population) will define the commercial landscape - whoever gets there first with FDA approval captures the referral networks. Azenosertib's DENALI Part 2 readout expected by end of 2026 could force Incyte's hand on timeline [10]. The CDK2 class competitors (Pfizer's tegtociclib, Blueprint's BLU-222) are 2-3 years behind in registrational development [13][14]. From a corporate perspective, this program carries outsized strategic importance. Jakafi generated $3.09B in FY2025 revenue - 60% of Incyte's $5.14B total - and its composition-of-matter patents expire in late 2028 (extended to approximately December 2028 with pediatric exclusivity) [4][12][15]. The revenue cliff is real and approaching fast. Incyte needs INCB123667 and its broader CDK2 franchise (including first-line maintenance ovarian cancer, breast, and endometrial expansions) to become a meaningful contributor before Jakafi generics arrive. If MAESTRA-2 succeeds, a 2029-2030 launch with $250-500M US peak revenue potential would provide partial but significant offset. If it fails, Incyte's pipeline gap becomes considerably harder to bridge. Check back at ASCO 2026 for updated MAESTRA-1 enrollment data and any interim looks.